Preclinical evaluation of 18F-labeled tozadenant analogs as potential PET tracers for cerebral A2A adenosine receptors
Nuklearmedizin - NuclearMedicine · 01.03.2024 · 63 (02) · 151-152
DOI: 10.1055/s-0044-1782466 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.03.2024. Verfasst von F. Wedekind und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Wedekind, F., Lang, M., Humpert, S., Schneider, D., Drechsel, A., Klein, S., Mottaghy, F. M., Tolba, R., Neumaier, B., Drzezga, A., & Bauer, A. (2024). Preclinical evaluation of 18F-labeled tozadenant analogs as potential PET tracers for cerebral A2A adenosine receptors. Nuklearmedizin - NuclearMedicine, 63(02), 151-152. https://doi.org/10.1055/s-0044-1782466
Vancouver
Wedekind F, Lang M, Humpert S, Schneider D, Drechsel A, Klein S, et al. Preclinical evaluation of 18F-labeled tozadenant analogs as potential PET tracers for cerebral A2A adenosine receptors. Nuklearmedizin - NuclearMedicine. 2024;63(02):151-152. doi:10.1055/s-0044-1782466
BibTeX
@article{Wedekind2024,
author = {Wedekind, F. and Lang, M. and Humpert, S. and Schneider, D. and Drechsel, A. and Klein, S. and Mottaghy, F. M. and Tolba, R. and Neumaier, B. and Drzezga, A. and Bauer, A.},
title = {Preclinical evaluation of 18F-labeled tozadenant analogs as potential PET tracers for cerebral A2A adenosine receptors},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2024},
volume = {63},
number = {02},
pages = {151--152},
doi = {10.1055/s-0044-1782466}
}
EUVIMED